RE: Its time the board delivered!1 Jun 2024 21:17
Stephen, you keep referring to imminent news about an US FDA partner. Was that not the RNS of 24th April? Or, are you expecting something else?
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces that it has entered into a Clinical Trial Agreement with a leading multi-state physician organisation ("Research Partner") in the USA to support clinical studies required for engagement with the U.S. Food and Drug Administration ("FDA") to progress the regulatory approval of the Genedrive® MT-RNR1 ID Kit into the USA via the FDA De novo submission process.
In 2021, 3.7 million babies were born in the United States, with 10.5% born prematurely1. It has been estimated that malpractice litigation settlements in cases related to deafness caused by the use of aminoglycosides average over US$1.1 million per case2, further adding to the positive health economic case of providing accurate and timely testing to reduce unwanted side effects of gentamicin usage.
The Genedrive® MT-RNR1 ID Kit is the world's first point-of-care genetic test to reduce the risk of antibiotic induced hearing loss (AIHL). Following detection of the MT-RNR1 variant an alternative antibiotic treatment can be prescribed. It has the potential to save thousands of children from lifelong hearing loss, whilst providing a net positive financial outcome case to healthcare systems.
The FDA De Novo pathway provides a vehicle for establishing new predicate devices that can reflect modern standards for performance and safety and can serve as a basis for future clearances. De Novo classification is a risk-based classification process used when there is a lack of predicate device already cleared by the FDA. Our partnership enables affordable access for clinical studies in NICU sites in the United States as required for the FDA de novo submission process, with a leading multi-state physician organisation with expertise and coverage of US neonatal services.
Sign In
Follow the stocks
